Autopsy report · NCT00346229
Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer
Cause of deathFunding or business
“Funding”
Life of this trial
- Registered 2 months after it had already started.
- Ran for about 5 years before it stopped.
- 29 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Duke University
- Sponsor type
- University, hospital or other
- Conditions
- Breast Cancer
- Interventions
- filgrastim; pegfilgrastim; lyso-thermosensitive liposomal doxorubicin(Thermodox); hyperthermia treatment
- Participants
- 29
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.